Navigation Links
3SBio Inc. Schedules Third Quarter 2010 Unaudited Financial Results

3SBio Inc. Schedules Third Quarter 2010 Unaudited Financial Results -- SHENYANG, China, Oct. 18 /PRNewswire-Asia-FirstCall/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals Click to view news release full screen  

3SBio Inc. Schedules Third Quarter 2010 Unaudited Financial Results


SHENYANG, China, Oct. 18 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release unaudited financial results for the third quarter ended September 30, 2010 after the Nasdaq Stock Exchange closes on Monday, November 15, 2010 at 8:00pm (Eastern).

Following the earnings announcement, 3SBio's senior management will host a conference call at 5:00am (Pacific) / 8:00am (Eastern) / 9:00pm (Beijing/Hong Kong) on Tuesday, November 16, 2010 to discuss its 2010 third quarter financial results and recent business activity. The conference call may be accessed using the dial-in numbers below:

Conference ID: 18843960 Local dial-in: China landline 800-819-0121 China mobile 400-620-8038 Hong Kong 852-2475-0994 International toll-free dial-in: Hong Kong 800930346 United Kingdom 080-8234-6646 United States 1-866-519-4004 International toll dial-in: 65 6723 9381 Replay - Conference ID: 18843960

A telephone replay will be available two hours after the call until November 22, 2010, at:

International dial-in: 61-2-8235-5000 United States dial-in: 1-866-214-5335


A live webcast of the conference will be available on the investor relations page of 3SBio's website at and at . A replay of the webcast will be available within one hour after the conclusion of the call.

About 3SBio Inc.

3SBio is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China. Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. With headquarters and GMP certified manufacturing facilities in Shenyang, PRC, 3SBio employs over 500 people. Shares trade in the form of American Depositary Shares (ADSs) on the NASDAQ stock market under the ticker symbol "SSRX". Please see for more information.

Investor Contacts Bo Tan Chief Financial Officer 3SBio Inc. Tel: +86-24-2581-1820 Email: Tom Folinsbee Director of Investor Relations 3SBio Inc. Tel: +852-8191-6991 Email:

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. 3SBio Announces Partial Conversion of Isotechnika Debenture
2. 3SBio Announces Investor Conference Schedule
3. 3SBio and Isotechnika Pharma Announce Strategic Partnership to Develop and Commercialize Voclosporin in China
4. 3SBio Inc. Announces Results of Annual General Meeting
5. FDA Schedules Third Orphan Drug Workshop for Nov. 4-5, 2010
6. Varian Medical Systems Schedules Fourth Quarter FY2010 News Release and Conference Call
7. Misonix Schedules Fourth Quarter and Fiscal 2010 Financial Results Conference Call; September 28, 2010 at 4:30 p.m. Eastern
8. Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results
9. Varian Medical Systems Schedules Investor Meeting and Fiscal Year End Review at ASTRO in San Diego, November 2, 2010
10. Sunridge Schedules European Meetings
11. Unilife Corporation Schedules Fiscal 2010 Fourth Quarter and Year End Conference Call for Monday, August 30, 2010
Post Your Comments:
(Date:11/26/2015)... November 26, 2015 ... the "Radioimmunoassay Market by Type (Reagents ... Industry, Academics, Clinical Diagnostic Labs), Application (Research, ... to 2020" report to their offering. ... the addition of the "Radioimmunoassay Market ...
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
(Date:11/25/2015)... , Nov. 25, 2015 On Tuesday, ... federal bellwether trial against Wright Medical Technology, Inc. ... their Conserve metal-on-metal hip implant device, awarded $11 ... a two week trial and three days of ... hip device was defectively designed and unreasonably dangerous, ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 2015 , ... Indosoft Inc., developer and distributor of the ... LTS (Long Term Support) into its Q-Suite 5.10 product line. , Making the ... a version of Asterisk that will receive not only security fixes, but feature ...
(Date:11/26/2015)... NV (PRWEB) , ... November 26, 2015 , ... Inevitably ... strategy. Many customers choose to buy during the Black Friday and Cyber Monday ... Shoppers don’t need to search the Internet high and low to find the best ...
(Date:11/26/2015)... ... 26, 2015 , ... Somu Sivaramakrishnan announced today that he ... now offers travelers, value and care based Travel Services, including exclusive pricing on ... as, cabin upgrades and special amenities such as, shore excursions, discounted fares, travel ...
(Date:11/26/2015)... , ... November 26, 2015 , ... Jobs in hospital ... healthcare professionals and offered by healthcare staffing agency Aureus Medical Group . ... month of October 2015 among those searching for healthcare jobs through the company’s website, ...
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare International, ... in the 61st annual Employee Benefits Conference. The Employee Benefits Conference was hosted ... 8th through Wednesday, November 11th, 2015. The conference was held at the Hawaii ...
Breaking Medicine News(10 mins):